Screener
Anika Therapeutics ANIK Business Segments — Cost of Goods Sold
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Anika Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Anika Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001171843-26-005012
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenue | $32,610 | $28,219 | $62,222 | $54,387 |
| Cost of product revenue | 11,366 | 13,856 | 21,981 | 25,343 |
| Gross Profit | 21,244 | 14,363 | 40,241 | 29,044 |
| Operating expenses: | ||||
| Research & development | 7,341 | 6,313 | 14,054 | 12,372 |
| Selling, general & administrative | 10,949 | 12,230 | 28,721 | 25,136 |
| Total operating expenses | 18,290 | 18,543 | 42,775 | 37,508 |
| Income (loss) from operations | 2,954 | (4,180) | (2,534) | (8,464) |
ITEM 1. FINANCIAL STATEMENTS[ Item 1. Condensed Consolidated Financial Statements (unaudited): ](#)
FAQ
- What is Anika Therapeutics's business segments — cost of goods sold?
- Anika Therapeutics (ANIK) reported business segments — cost of goods sold of $11.37M in Q2 2026.
- What does business segments — cost of goods sold mean?
- This reflects the direct costs associated with manufacturing and delivering the company's orthopedic therapies and regenerative solutions. Monitoring this helps evaluate production efficiency and the impact of raw material or supply chain fluctuations on the core business.
Ask your AI about Anika Therapeutics's business segments — cost of goods sold.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude